Neurology · DepressionTrial Updateclinicalmid-term

Phase I Trial of Ammoxetine Hydrochloride in Hepatic Impairment Patients

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/11/2026, 6:03:18 AM

Assessment confidence: 82% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing Phase I trial of ammoxetine hydrochloride in patients with hepatic impairment is crucial as it may shape dosing guidelines and safety assessments for this drug. Positive results could enhance its competitive positioning in the neurology market, particularly for depression treatments. Regulatory context from FDA (FDA AP — AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE (SUPPL)) supports the near-term read. Assessment grounded in 19 ranked evidence items (16 high-relevance).

Strategic Assessment

Results from this trial could inform dosing guidelines and safety assessments, impacting future development strategies for ammoxetine. The strongest clinical anchor is A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No (ClinicalTrials.gov), entity match (cspc zhongqi pharmaceutical technology co ltd ). In Neurology · Depression, 7 regulatory and 1 competitive items passed relevance filtering for CSPC ZhongQi Pharmaceutical Technology Co., Ltd..

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). This trial may provide insights into the safety profile and dosing considerations of ammoxetine in a specific patient population, potentially influencing its market positioning against competitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE (SUPPL) (FDA). Regulatory pathway relevance (nda). Outcomes from this trial may affect regulatory submissions and labeling for ammoxetine, particularly regarding its use in patients with hepatic impairment.

Key Risks

Elevated medium regulatory exposure for CSPC ZhongQi Pharmaceutical Technology Co., Ltd. could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The trial results could influence market share and revenue potential for ammoxetine, especially if it demonstrates a favorable safety profile in a challenging patient population.
Upside for CSPC ZhongQi Pharmaceutical Technology Co., Ltd. may improve if A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB) (ClinicalTrials.gov) delivers favorable follow-through.
Lead sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.. This is a multicenter, randomized, open-label, parallel-group, Phase II clinical trial designed to evaluate the efficacy and safety of HW211026 in adult patients with actinic keratosis.
Results from this trial could inform dosing guidelines and safety assessments, impacting future development strategies for ammoxetine.

What Would Change This Assessment

This becomes more urgent if Monitor for trial results and any safety signals that may emerge from the pharmacokinetic analysis.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VERAPAMIL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — NILOTINIB HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Compounding Safety Information: Quinacrine Hydrochloride
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govhigh relevance
Entity match (cspc zhongqi pharmaceutical technology co ltd )
FDA document
View source
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase 2 Study of HW211026
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
ammoxetine hydrochloride

Commercial impact

medium

The trial results could influence market share and revenue potential for ammoxetine, especially if it demonstrates a favorable safety profile in a challenging patient population.

Regulatory impact

medium

Outcomes from this trial may affect regulatory submissions and labeling for ammoxetine, particularly regarding its use in patients with hepatic impairment.

What to watch

Monitor for trial results and any safety signals that may emerge from the pharmacokinetic analysis.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.